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OBJECTIVES: To describe systemic glucocorticoid usage in cats and dogs by three primary care  veterinary 
practices in England and to ascertain risk factors for clinical use. To evaluate consistency of prescrib-
ing patterns across clinics. To validate a merged database of primary veterinary clinical data as a 
functional tool for clinical epidemiological research. 
METHODS: A merged database was established from clinical data on 31,273 cat and dog consultations 
with pharmacotherapy from three veterinary practices in England. Descriptive statistics described 
systemic glucocorticoid drug use in cats and dogs while mixed-effects logistic regression modelling 
evaluated risk factors. Individual clinic usage was compared.
RESULTS: Overall, 1877 (16·68%) cat consultations and 2913 (14·55%) dog consultations resulted in 
systemic glucocorticoid therapy. Cats received higher parenteral (P<0·0001) and oral (P<0·0001) 
dose levels than dogs. Pathophysiological indication, age, skin condition, sex and clinic attended were 
significant risk factors for glucocorticoid prescription. Clinics varied widely in their odds of systemic 
glucocorticoid usage (P<0·0001).
CLINICAL SIGNIFICANCE: An evidence base for systemic glucocorticoid prescribing by primary care small 
animal practices in England is provided. Clinic attended was a significant risk factor, indicating wide 
variation in prescribing patterns between clinics. A merged primary care veterinary clinical database 
was effective for epidemiological research.
INTRODUCTION
Glucocorticoids are among the most widely used (and misused) 
class of drugs in veterinary medicine; yet, there is little informa-
tion on prescribing patterns in general practice (Ferguson and 
others 2009). Glucocorticoids are potent anti-inflammatory and 
immunosuppressive agents and the majority of therapeutic appli-
cations for these agents fall into these classifications (Ferguson 
and others 2009). Glucocorticoids are also indicated to treat 
deficiency states, neoplasia and as antishock agents (Rang and 
others 2007). Because of the presence of glucocorticoid recep-
tors in almost all cells, both the desired and undesired effects of 
 glucocorticoid therapy are manifold, making the need for prudent 
use particularly important (Behrend and Kemppainen 1997). 
Hill and others (2006) showed that systemic glucocorticoids 
were prescribed in 162 of 795 (20%) skin cases in primary care 
practice. However, prescribing data for general small animal case-
loads is lacking. Increasing computerisation within small animal 
veterinary practice (94% of UK practices use a computerised 
system for client details (Robinson and Hooker 2006)) means 
that collaborative research projects can now capture and analyse 
primary care clinical data.
The primary objectives of this study were to describe prescrib-
ing practices and ascertain risk factors for systemic glucocorticoid 
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2010) and dog breeds by dog-size based on height at the shoul-
der (small: <23 cm, medium: 23 to 46 cm, large: 47 to 61 cm, 
giant: >62 cm) (American Kennel Club 2011, The Kennel Club 
2011a,b). Crossbreeds were the referent for analysis. “Age” was 
categorised into life stages (<1 year, 1 to 6·99 years, 7 to 11·99 
years and >12 years). “Month” and “Season” variables were gen-
erated (spring: March to May, summer: June to August, autumn: 
September to November, winter: December to February). 
Assigned summary diagnoses were categorised as skin disease 
and also by pathophysiological indication for systemic gluco-
corticoid treatment: physiological (glucocorticoid deficiency), 
inflammatory (not including hypersensitivity conditions), hyper-
sensitivity, immunosuppressive, neoplastic, shock/spinal trauma, 
no apparent indication. 
Treatment data were searched for systemic glucocorticoid 
branded and generic names (NOAH 2010). Active ingredient 
doses were calculated for parenteral by injection (mg/kg body-
weight) and oral (daily mg/kg bodyweight) treatments based 
on recorded bodyweights. Initial dose was used where oral dose 
changed over time. Oral and parenteral dosages were categorised 
as low or high based on average recommended dosages (Table 1) 
(Ramsey 2007, NOAH 2010) Parenteral formulations were cat-
egorised as short-acting (duration <5 days): dexamethasone sodi-
um phosphate (Colvasone, Norbrook; Dexadreson, Intervet UK 
Ltd; Duphacort Q, Fort Dodge Animal Health), methylprednis-
olone sodium succinate (Solu-Medrone V; Pfizer Limited), dexa-
methasone isonicotinate (Voren; Boehringer Ingelheim Limited) 
or long-acting (duration >5 days): dexamethasone phenylpropio-
nate/dexamethasone sodium phosphate combination (Dexafort; 
Intervet UK Ltd), methylprednisolone acetate (Depo-Medrone 
V; Pfizer Limited) (Table 1) (NOAH 2010). 
Statistical analysis used Stata Version 11 (Stata Corp.) and 
was separated by cats and dogs. Prevalence of glucocorticoid 
usage was evaluated by standard methods (Kirkwood and Sterne 
2003). Inter-species usage levels were compared using the Mann- 
Whitney U test. Risk factor analysis used mixed-effects logistic 
regression with animal ID as a random effect to account for clus-
tering of consultations within animals. Statistical significance was 
set at the 5% level or where an a priori interest dictated inclusion.
use in cats and dogs by three primary care veterinary practices in 
England and to explore prescribing level variation between clin-
ics. A secondary objective was to validate a merged database of 
primary veterinary electronic patient records for epidemiological 
research. 
MATERIALS AND METHODS
Participants and procedure
This study was a retrospective analysis of all clinical records from 
three small animal veterinary practices in England participat-
ing between January 01, 2007 and December 31, 2009 within 
the pilot phase for the VetCompass Animal Surveillance project 
(VetCompass 2011). Practice selection was a convenience sample 
using RxWorks practice management system (PMS) (RxWorks 
2011) and willingness to participate. Participating practices 
assigned consultations with summary diagnoses from the VeNom 
Code list of veterinary-specific terms (The VeNom Coding Group 
2011). PMS data fields captured included unique clinic, animal 
and consultation numbers, consultation date, veterinarian initials, 
species, breed, sex, neutering status, birth-date, weight, clinical 
notes, summary diagnosis and treatment. Systemic glucocorti-
coids were defined as glucocorticoid products administered either 
parenterally or orally. Consultations were defined as same-day 
“episodes of care” involving a cat or dog by a single veterinarian 
resulting in pharmacotherapy. Ethics approval was granted by the 
Royal Veterinary College Ethics & Welfare Committee.
Data analysis
An integrated query extracted clinical data from individual 
PMS’s (Upjohn and others 2008) for checking and cleaning in 
a spreadsheet (Microsoft Office Excel 2007, Microsoft Corp.). 
Non-veterinarian, non-cat/non-dog and non-pharmacothera-
peutic observations were removed. Breed type was assigned by the 
owner or veterinary practice based on phenotype and categorised 
as “Breed status” (purebreed or crossbreed) and “Breed status” 
(purebreed, dominant cross or crossbreed). Cat breeds were fur-
ther categorised by cat-type (shorthaired or longhaired) (TICA 
Table 1. Parenteral and oral glucocorticoid dose-level cut-points used to categorise dosages as low or high and summary 
statistics for the cat and dog dosages used in three UK small animal practices
Glucocorticoid name Cats Dogs
Cut-point No. Obs Med Range Cut-point No. Obs Med Range
Parenteral mg/kg
Methylprednisolone acetate 2·00 343 4·62 1·93 to 10·81 1·00 14 1·38 0·26 to 5·03
Dexamethasone sodium phosphate 0·15 301 0·20 0·05 to 3·5 0·10 511 0·10 0·08 to 0·96
Dexamethasone phenylpropionate and 
Dexamethasone sodium phosphate
0·15 411 0·35 0·12 to 1·78 0·15 88 0·21 0·04 to 0·48
Methylprednisolone sodium succinate 30·00 0 N/A N/A 30·00 2 11·64 4·06 to 19·23
Dexamethasone isonicotinate 1·0 4 0·27 0·18 to 0·3 1·0 4 0·30 0·22 to 0·41
Oral mg/kg daily
Fludrocortisone 0·02 0 N/A N/A 0·02 2 0·02 0·01 to 0·02
Methylprednisolone 1·00 7 0·39 0·27 to 1·07 0·35 115 0·33 0·05 to 1·13
Prednisolone/Cincophen* N/A 0 N/A N/A 0·62 12 0·11 0·05 to 0·15
Prednisolone 1·10 120 0·78 0·08 to 3·70 0·50 407 0·53 0·01 to 5·00
No. Obs Number of observations, Med Median dosage, N/A Not applicable
*Prednisolone dose only
Journal of Small Animal Practice  •  Vol 53  •  April 2012  •  © 2012 British Small Animal Veterinary Association 219 
Primary care glucocorticoid usage in cats and dogs
 
RESULTS
Three practices contributed 31,273 consultations with pharma-
cotherapy [11,254 (35·99%) cat and 20,019 (64·01%) dog]. Two 
practices were single-centre [4880 (15·60%) and 7735 (24·73%) 
consultations] while the third comprised five clinics [18,658 
(59·66%) consultations]. The 24 veterinarians contributed from 
5 to 3798 consultations each (median: 647). Overall, 4790 
(15·32%) of consultations resulted in systemic glucocorticoid 
pharmacotherapy; 2878 (9·20%) parenteral only, 1675 (5·36%) 
oral only and 237 (0·76%) both parenteral and oral (Table 2). 
Frequency and mode of glucocorticoid treatment in 
cats and dogs
Comparing the species, cats had 1·18 [95% confidence interval 
(CI) 1·10 to 1·25, P<0·0001] times the odds of systemic gluco-
corticoid pharmacotherapy and 8·85 (95% CI 7·38 to 10·60, 
Table 2.  Glucocorticoid usage statistics for cat and 
dog consultations that include systemic glucocorticoid 
pharmacotherapy 
Cat* Dog*
Frequency Percent 
(%)
Frequency Percent 
(%)
Mode of administration
Only parenteral 
glucocorticoid
1651 87·96 1227 42·12
Only oral 
glucocorticoid
196 10·44 1479 50·77
Both  parenteral 
and oral 
glucocorticoid
30 1·60 207 7·11
Parenteral formulation used 
Short-acting 475 28·26 1053 73·43
Long-acting 1206 71·74 381 26·57
Oral glucocorticoid active ingredient
Fludrocortisone 0 0 8 0·47
Methylprednisolone 23 10·18 390 23·13
Prednisolone and 
cinchophen 
tablets
0 0 47 2·79
Prednisolone 203 89·82 1241 73·61
Oral glucocorticoid dose schedule†
Once weekly 8 3·54 19 1·13
Once every 4 days 2 0·88 0 0
Twice weekly 0 0 1 0·06
Every third day 7 3·10 14 0·83
Three times weekly 4 1·77 6 0·36
Every other day 42 18·58 188 11·15
Four times weekly 0 0 1 0·06
Daily 113 50·00 734 43·53
Twice-daily 50 22·12 721 42·76
Three times daily 0 0 2 0·12
Parenteral dose level based on recommended species doses‡
Low 90 8·50 181 29·24
High 969 91·50 438 70·76
Oral dose level based on recommended species doses‡
Low 86 67·72 261 48·69
High 41 32·28 275 51·31
*A total of 1877 (16·68%) cat and 2913 (14·55%) dog consultations resulted in treat-
ment with or dispensation of systemic glucocorticoids
†Where an oral prescription specified a dose changing with time, the initial dose was 
used
‡Dosage cut-points for dose-level categories are given in Table 1
P<0·0001) times the odds of parenteral therapy than dogs. 
Parenteral dose levels were significantly higher for cats than dogs 
for methylprednisolone acetate (Depo-Medrone V; Pfizer Limited) 
(median cat 4·62 mg/kg versus median dog 1·38 mg/kg, P<0·0001) 
and dexamethasone sodium phosphate (Colvasone; Norbrook; 
Dexadreson, Intervet UK Ltd; Duphacort Q, Fort Dodge Animal 
Health) (median cat 0·20 mg/kg versus median dog 0·10 mg/kg, 
P<0·0001). Cat oral daily dose levels significantly exceeded dogs 
for prednisolone (median cat 0·78 mg/kg/daily versus median dog 
0·53 mg/kg/daily, P<0·0001) (Table 1). Cats were significantly 
more likely to have lower oral dosing frequencies than dogs (once-
daily or less: cat 77·88% versus dog 57·12%, P=0·0002) (Table 2). 
For cat consultations, 1877 (16·68%) employed systemic glu-
cocorticoids with 1651 (87·96%) of these employing only paren-
teral therapy. The majority of parenteral formulations (71·74%) 
were long-acting. For cat oral glucocorticoid dose regimens, 
50·00% were once-daily while 22·12% were twice-daily. Dosages 
were “high” for 91·50% of cat parenteral doses and 32·28% of 
cat oral treatments (Table 2). 
Among dogs, 2913 (14·55%) of consultations employed sys-
temic glucocorticoids with 1227 (42·12%) of these including 
only parenteral therapy. Of dog parenteral treatments, 26·57% 
were long-acting formulations. Prednisolone (73·61%) and 
methylprednisolone (Medrone V Tablets; Pfizer Ltd) (23·13%) 
were the most common oral preparations. Once-daily and twice-
daily oral dose regimens covered 43·53 and 42·76% of oral doses, 
respectively. Dose-levels were “high” for 70·76% of dog paren-
teral treatments and 51·31% of dog oral treatments (Table 2).
Risk factors for glucocorticoid treatment in cats
Five predictors were retained in the final cat multivariable model 
(Table 3): “Pathophysiological indication”, “Age”, “Skin”, “Sex” 
and “Clinic”. 
Compared with inflammatory conditions, consultations for 
neoplastic conditions had 4·28 (95% CI 2·93 to 6·24, P<0·0001) 
times the odds of receiving systemic glucocorticoids while con-
sultations with no record of an apparent glucocorticoid indica-
tion had 0·39 times the odds (95% CI 0·31 to 0·49, P<0·0001). 
Cats 1 to 7 years old had 3·41 times the odds of receiving a sys-
temic glucocorticoid (95% CI 2·00 to 5·81, P<0·0001) than cats 
under one year old, while 7 to 12 year-old cats had 6·37 times the 
odds (95% CI 3·69 to 10·98, P<0·0001). 
Male cats had 0·72 (95% CI 0·57 to 0·90, P=0·0011) times 
the odds of treatment compared with female cats. Consulta-
tions at Clinic C5 had 2·66 (95% CI 1·62 to 4·40, P<0·0001) 
the odds compared with Clinic A. Prescribing levels within the 
multi-centre practice clinics (C1-C5) appeared more uniform 
than in comparison with the two single practices (A and B). 
Risk factors for glucocorticoid treatment in dogs
The final dog multivariable model retained five risk factors 
(Table 4): “Pathophysiological indication”, “Age”, “Skin”, “Sex” 
and “Clinic”. Consultations with no record of an apparent gluco-
corticoid indication had 0·54 (95% CI 0·46 to 0·66, P<0·0001) 
times the odds of receiving systemic glucocorticoids compared with 
inflammatory conditions. Dogs 7 to 12 years old had 1·55 times the 
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Table 3. Final mixed-effects model for risk factors 
associated with systemic glucocorticoid therapy for CAT 
consultations 
Risk factor Odds ratio 95% CI P-value
Pathophysiological indication
Anti-inflammatory (not 
including hypersensitiv-
ity conditions)
1·00 Reference <0·0001
Hypersensitivity 61·65 38·62 to 98·44
Immunosuppressive 13·65 7·64 to 24·39
Neoplastic 4·28 2·93 to 6·24
Shock/spinal trauma 4·16 1·74 to 9·98
No apparent indication 
for glucocorticoid
0·39 0·31 to 0·49
Age
<1 year 1·00 Reference <0·0001
1 to 6·99 years 3·41 2·00 to 5·81
7 to 11·99 years 6·37 3·69 to 10·98
12 years and older 9·17 5·36 to 15·68
Skin
No skin condition 
diagnosed
1·00 Reference <0·0001
Skin condition diagnosed 3·64 2·75 to 4·80
Sex
Female 1·00 Reference 0·0011
Male 0·72 0·57 to 0·90
Clinic
A 1·00 Reference 0·0027
B 2·76 1·77 to 4·31
C1 1·51 0·63 to 3·61
C2 1·63 1·05 to 2·53
C3 1·91 1·27 to 2·87
C4 1·30 0·85 to 1·99
C5 2·66 1·62 to 4·40
Random effect
Animal ID — 1·94 to 3·10
Table 4. Final mixed-effects model for risk factors 
 associated with systemic glucocorticoid therapy for DOG 
consultations
Risk factor Odds ratio 95% Confidence 
interval
P-value
Pathophysiological indication
Anti-inflammatory (not 
including hypersensitiv-
ity conditions)
1·00 Reference
<0·0001
Physiological 78·92 13·72 to 453·89
Hypersensitivity 6·91 5·52 to 8·64
Immunosuppressive 3·88 2·60 to 5·79
Neoplastic 1·08 0·78 to 1·49
Shock/spinal trauma 3·58 2·01 to 6·38
No apparent indication 
for glucocorticoid
0·54 0·46 to 0·66
Age category 
<1 year 1·00 Reference <0·0001
1 to 6·99 years 1·26 0·98 to 1·63
7 to 11·99 years 1·55 1·18 to 2·03
12 years and older 2·07 1·52 to 2·83
Sex
Female 1·00 Reference 0·0650
Male 1·16 0·99 to 1·35
Skin
No skin condition 
diagnosed
1·00 Reference <0·0001
Skin condition 
diagnosed
6·75 5·81 to 7·85
Clinic
A 1·00 Reference <0·0001
B 1·27 1·01 to 1·61
C1 0·74 0·44 to 1·25
C2 0·45 0·34 to 0·61
C3 0·61 0·48 to 0·78
C4 0·49 0·37 to 0·65
C5 0·75 0·55 to 1·02
Random effect
Animal ID — 1·53 to 2·17
odds of receiving a systemic glucocorticoid (95% CI 1·18 to 2·03, 
P<0·0001) than dogs under 1 year old while dogs over 12 years 
old had 2·07 times the odds (95% CI 1·52 to 2·83, P<0·0001). 
Diagnosis of a skin condition increased the odds of receiving glu-
cocorticoid therapy 6·75 (95% CI 5·81 to 7·85, P<0·0001) times. 
Male dogs had 1·16 (95% CI 0·99 to 1·35, P=0·0650) times the 
odds of treatment compared with female dogs. Dog consultations 
at Clinic C2 had 0·45 (95% CI 0·34 to 0·61, P<0·0001) times the 
odds of glucocorticoid therapy compared with Clinic A.
DISCUSSION
Overall, systemic glucocorticoid prescribing was common 
(15·32% of consultations) in accordance with the importance 
of glucocorticoid therapy (Ferguson and others 2009) but lower 
than the 20% recorded by Hill and others (2006) for skin con-
ditions. Although statistically significantly different, the clinical 
significance of the prescribing frequency variation between cats 
(16·68%) and dogs (14·55%) would appear limited. Glucorticoid-
treated cats were significantly more likely to receive parenteral 
format treatment than dogs, possibly because pill administration 
is difficult for many owners (Norsworthy 2006). Behrend (1997) 
recommended avoidance of repository  glucocorticoid therapy for 
dogs but this study found that 26·57% of dog parenteral treat-
ments employed long-acting formulations.
Both parenteral and oral glucocorticoid dosages were higher 
for cats than dogs, in agreement with general recommendations 
(Ramsey 2007, NOAH 2010) and reflecting more frequent side 
effects in the dog than the cat (Lowe and others 2008). A sys-
tematic review of oral glucocorticoid therapy for canine atopic 
dermatitis reported adverse drug events in 10 to 81% of dogs 
treated (Olivry and others 2010), while glucocorticoid treatment 
is typically well tolerated by cats (Lowe and others 2008). Vet-
erinarians were more likely to use high dose levels for parenteral 
than for oral doses. This may result from the relatively high drug 
concentrations and small volumes of parenteral preparations or 
perceived reduced side effects from single parenteral doses in 
comparison with repeated oral dosing regimens. Although gluco-
corticoid recommended doses vary greatly between specific con-
ditions, this study used general cut-points to provide an overall 
description of dosing regimens. No attempt was made to evaluate 
the appropriateness of dosages for the underlying conditions.
Risk factor analysis for systemic glucocorticoid administration 
was carried out separately for cats and dogs because of differ-
ences in pharmacodynamics (Lowe and others 2008), pragmatic 
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approach to drug administration (Norsworthy 2006) and vet-
erinary perception of drug-safety differences between the species 
(Sturgess 2002). 
Pathophysiological indication was highly predictive for both 
species, as would be expected from the widespread use and var-
ied clinical indications for glucocorticoids (Sturgess 2002). Cats 
with neoplastic conditions had over four times the odds of glu-
cocorticoid therapy compared with inflammatory conditions. 
Glucocorticoids at anti-inflammatory dose levels provide pal-
liative management of certain neoplasms, whereas even higher 
doses may also have a direct antineoplastic effect on tumours 
such as lymphoma (LeCouteur 2007). There was a surprisingly 
high level of glucocorticoid use in conditions where an apparent 
indication for glucocorticoid use was not recorded for both cats 
and dogs. Glucocorticoids can induce non-specific reduction of 
clinical symptoms but Sturgess (2002) advises that corticoste-
roids should be reserved for specific purposes. 
Skin disease increased treatment odds threefold in cats and 
sixfold in dogs, likely reflecting a perceived underlying inflam-
matory component to many skin conditions as well as demands 
by owners for rapid relief of clinical signs (pruritus, erythema) 
(Olivry and Mueller 2003). 
Advancing age was a significant predictor for both cats and 
dogs. Reduced glucocorticoid therapy for kittens and puppies 
reflects good practice; glucocorticoids suppress growth hor-
mone and somatostatin-mediated osteoblast function (Sturgess 
2002). Increasing occurrence of conditions with a glucocorticoid 
 therapy indication as animals age could explain this age-related 
trend; a study on Swedish dogs showed that 10-year-old dogs 
had twice the odds of inflammatory conditions and 14 times 
the odds of neoplastic conditions as 2-year-old dogs (Bonnett 
and Egenvall 2010). The finding that male cats had lower odds 
of glucocorticoid treatment while male dogs had higher odds is 
difficult to explain biologically. “Clinic identity” was a signifi-
cant risk factor for both cats and dogs. Clinics comprising an 
overall practice group were more comparable in prescribing pat-
terns than the stand-alone clinics, possibly demonstrating shared 
prescribing determinants within the multi-centre practice. These 
findings suggest that systemic glucocorticoid prescribing prac-
tices are determined less by overall veterinary medical diktat and 
more by practice protocol, clinical experience and personal opin-
ion. Formal evidence-based guidance on the therapeutic use of 
systemic glucocorticoids in clinical practice may improve clinical 
outcomes whilst minimising drug-related side effects.
Several limitations are worth noting. The study included only 
consultations with pharmacotherapy to allow a robust “con-
sultation” definition and will therefore over-estimate overall 
glucocorticoid prescribing levels. Coprescribing of alternative 
anti-inflammatory/immunosuppressive agents or topical gluco-
corticoid products was not examined. Veterinarians recorded the 
most important diagnoses pertaining to each specific visit but 
may not have recorded underlying comorbid conditions which 
could have contributed to the recorded high level of usage for 
cases without an apparent clinical indication. Practice selection 
was a convenience sample, potentially introducing selection bias 
and limiting generalisation of the results. 
The study validated a “proof of concept” that primary veteri-
nary practice clinical data can be successfully merged to create 
an effective research database. Although over 30,000 cat and dog 
consultations were included, an increased number of participat-
ing practices will be required to robustly generalise results. 
CONCLUSIONS
This study described prescribing practices and evaluated risk 
factors for systemic glucocorticoid pharmacotherapy in a large 
cohort of UK cats and dogs attending three practices and vali-
dated the role of electronic patient records for research. Systemic 
glucocorticoid therapy is common. Pathophysiological indica-
tion, advancing age, sex, skin conditions and clinic attended 
were significant risk factors for systemic glucocorticoid therapy 
for both species. Further studies to explore the wide variations 
in prescribing behaviour across practices could help optimise 
prescribing and identify factors affecting drug use itself and also 
drug use patterns that fall outside recommended prescribing 
behaviour.
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